AHEAD 3-45 Study Data Use Agreement
One-time, non-transferable license for an approved research proposal. No commercialization or redistribution, strict confidentiality and AI-tool safeguards, safety findings must be reported to Eisai within 24 hours, Eisai and USC get a license to any new invention and Eisai an option for an exclusive license, users from countries of concern are excluded, and the data must be destroyed after five years.
Our reading of the license, not legal advice. Before you use the data, read the original license and confirm that your use is allowed. We take no responsibility for how you use a dataset. Full disclaimer
What you can do
- No
- Not stated
- Conditional
- Not stated
- Conditional
What you can share
- No
- Not stated
- Not stated
What you must do
- Yes
- Share alike No
- Yes
- No
- No
- Conditional
- Conditional
- Yes
Limits
- Yes
- Conditional
Separate commercial license: Not stated No commercial license offer is published; the agreement states the data package shall not be commercialized.
Datasets under this license
- AHEAD 3-45 screening data
Amyloid PET and cognitive testing from the screening stage of lecanemab prevention trials in cognitively unimpaired adults aged 55 to 80, shared for research on preclinical Alzheimer's disease and trial recruitment. 16,835 North American screens; data after randomization are not shared.